What question did this study set out to answer?

To evaluate the efficacy of venetoclax-obinutuzumab therapy in achieving remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia.

March 16, 2026Open Access

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia

Key Points

To evaluate the efficacy of venetoclax-obinutuzumab therapy in achieving remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia.
Reported a case of a 72-year-old patient with chronic lymphocytic leukemia and acquired von Willebrand syndrome.
Initial treatments included VWF/FVIII concentrates and tranexamic acid.
Venetoclax-obinutuzumab therapy was initiated after persistent bleeding.
Monitoring of coagulation parameters and minimal residual disease was conducted.
Venetoclax-obinutuzumab successfully normalized factor VIII and von Willebrand factor levels.
Achieved undetectable minimal residual disease.
Indicated effective control of chronic lymphocytic leukemia and subsequent remission of acquired von Willebrand syndrome.

Abstract

Venetoclax-obinutuzumab therapy successfully induced remission of acquired von Willebrand syndrome (AVWS) in a 72-year-old patient with chronic lymphocytic leukemia (CLL). Initially diagnosed with CLL, the patient later experienced severe bleeding due to AVWS, as evidenced by reduced factor VIII (FVIII) and von Willebrand factor (VWF) levels. Despite initial treatment with VWF/FVIII concentrates and tranexamic acid, persistent bleeding prompted the initiation of venetoclax-obinutuzumab. This regimen resulted in normalization of coagulation parameters and undetectable minimal residual disease, indicating effective CLL control and subsequent AVWS remission. This case highlights the potential of targeted CLL therapies in the management of rare associated hematologic complications.

Bookmark

View Full Paper